Michael Nietzel is president emeritus of Missouri State University. A Forbes contributor since 2019, he writes about higher education. After earning his B.A. from Wheaton College (Illinois), he ...

"The School aims to enhance the way we use technology in research, food security, microbiology, ecosystem biology, sustainability and many other related areas. The School is dedicated to providing the ...

BofA Securities has recently resumed Gilead Sciences Inc (GILD) stock to Buy rating, as announced on December 10, 2024, according to Finviz. Earlier, on November 15, 2024, Wolfe Research had initiated ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other stocks Jim Cramer talked about. Jim Cramer, host of Mad Money, recently shared ...

We recently compiled a list of the Jim Cramer Talked About These 8 Stocks. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other stocks Jim ...

GS-1427 is under clinical development by Gilead Sciences and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase II drugs for Ulcerative Colitis have a 45% phase transition ...

BofA Securities has recently resumed Gilead Sciences, Inc. (GILD) stock to Buy rating, as announced on December 10, 2024, according to Finviz. Earlier, on November 15, 2024, Wolfe Research had ...

GS-0201 is under clinical development by Gilead Sciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR ...

GS-0201 is under clinical development by Gilead Sciences and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to GlobalData, ...

Gilead Sciences (Gilead) is a research-based biopharmaceutical company. It carries out the discovery, development and commercialization of medicines for the treatment of cardiovascular, hematological ...